1. Prof. Amnon Peled
Prof. Peled is an associate professor at the Gene Therapy Institute, Hadassah
Medical Center, Jerusalem where he directs a laboratory, focusing on the
role of chemokines and chemokine receptor in stem cell mobilization,
inflammation and cancer. The laboratory of Prof. Peled's support the
development of novel cell and molecular therapeutics for cancer and have
been involved in the last 9 years in the development of novel therapies to
cancer that are currently in Phase II. Prof. Peled worked in close collaboration
with Israeli Biotechnology companies such as Biokine Therapeutics LTD,
BiolineRX, and Gamida Cell. Prof. Peled has a Ph.D. from the Department of
Cell Biology at the Weizmann Institute of Science and is experience includes
time spent as a post Dr. at Harvard Medical School and Millennium
Pharmaceuticals Inc. Prof. Peled is also the founder of Biokine Therapeutics an
R&D biotechnology company founded in 2000. The company develops novel
therapeutics for cancer and inflammation. Prof. Peled has authored or co-
authored 89 papers and is listed as an inventor on over 70 patents related to
therapeutic applications in stem cell biology, immunology, and cancer.

2. List of publications 2011-2015
1. In the hunt for therapeutic targets: mimicking the growth, metastasis, and stromal
associations of early-stage lung cancer using a novel orthotopic animal model. Weiss
ID, Ella E, Dominsky O, Smith Y, Abraham M, Wald H, Shlomai Z, Zamir G,
Feigelson SW, Shezen E, Bar-Shai A, Alon R, Izhar U, Peled A, Shapira OM, Wald O.
J Thorac Oncol. 2015 Jan;10(1):46-58.
2. Multiple myeloma cells recruit tumor-supportive macrophages through the
CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Beider
K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, Abraham M,
Wald H, Galun E, Peled A, Nagler A. Oncotarget. 2014 Nov 30;5(22):11283-96.
3. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization
of human CD34+ cells in patients with multiple myeloma. Peled A, Abraham M, Avivi
I, Rowe JM, Beider K, Wald H, Tiomkin L, Ribakovsky L, Riback Y, Ramati Y, Aviel
S, Galun E, Shaw HL, Eizenberg O, Hardan I, Shimoni A, Nagler A. Clin Cancer Res.
2014 Jan 15;20(2):469-79.
4. Combination of Imatinib with CXCR4 antagonist BKT140 overcomes the protective
effect of stroma and targets CML in vitro and in vivo. Beider K, Darash-Yahana M,
Blaier O, Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O,
Peled A, Nagler A. Mol Cancer Ther. 2014 Feb 6. [Epub ahead of print].
5. Umbilical Cord Blood Stem Cells Expanded in the Presence of Nicotinamide (NiCord)
Provide Long Term Multi-lineage Engraftment. Mitchell E. Horwitz, Nelson J. Chao,
Patrick Stiff, David A. Rizzieri, Gwynn D. Long, Keith M. Sullivan, Cristina
Gasparetto, John P. Chute, Ashley Morris, Carolyn McDonald, Barbara Waters-Pick,
Steven Wease, Amnon Peled, David Snyder, Einat Galamidi Cohen, Hadas Shoham,
Efrat Landau, Etty Friend, Iddo Peleg, Dorit Aschengrau, Dima Yackoubov, Joanne
Kurtzberg, Tony Peled. JCI, 2014 Jul;124(7):3121-8.
6. Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes
megakaryopoiesis and platelet production. Abraham M, Weiss ID, Wald H, Wald O, Nagler A,
Beider K, Eizenberg O, Peled A. Br J Haematol. 2013 Oct;163(2):248-59. doi:
10.1111/bjh.12501. Epub 2013 Aug 1.
7. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-
affinity CXCR4 antagonist BKT140. Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L,
Rosenberg E, Galun E, Avigdor A, Eizenberg O, Peled A, Nagler A. Clin Cancer Res. 2013
Jul 1;19(13):3495-507. doi: 10.1158/1078-0432.CCR-12-3015. Epub 2013 May
8. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Peled A, Tavor S.
Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Review.
9. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Barashi N,
Weiss ID, Wald O, Wald H, Beider K, Abraham M, Klein S, Goldenberg D, Axelrod J, Pikarsky

3. E, Abramovitch R, Zeira E, Galun E, Peled A. Hepatology. 2013 Sep;58(3):1021-30. doi:
10.1002/hep.26403. Epub 2013 Jul 12.
10. Inhibition of nuclear factor-κB activation in pancreatic β-cells has a protective effect on
allogeneic pancreatic islet graft survival. Eldor R, Abel R, Sever D, Sadoun G, Peled A, Sionov
R, Melloul D. PLoS One. 2013;8(2):e56924. doi: 10.1371/journal.pone.0056924. Epub 2013
Feb 21.
11. Interstrain differences in chronic hepatitis and tumor development in a murine model of
inflammation-mediated hepatocarcinogenesis. Potikha T, Stoyanov E, Pappo O, Frolov A,
Mizrahi L, Olam D, Shnitzer-Perlman T, Weiss I, Barashi N, Peled A, Sass G, Tiegs G, Poirier
F, Rabinovich GA, Galun E, Goldenberg D. Hepatology. 2013 Jul;58(1):192-204. doi:
10.1002/hep.26335. Epub 2013 May 27.
12. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Peled A, Tavor S.
Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Review.
13. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-
small cell lung cancer. Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z,
Eizenberg O, Zamir G, Izhar U, Shapira OM, Peled A, Wald O. J Thorac Cardiovasc Surg.
2012 Nov;144(5):1167-1175.e1. doi: 10.1016/j.jtcvs.2012.07.031. Epub 2012 Aug 24.
14. Chemokine receptor expression in peripheral blood monocytes from patients with neovascular
age-related macular degeneration. Grunin M, Burstyn-Cohen T, Hagbi-Levi S, Peled A,
Chowers I. Invest Ophthalmol Vis Sci. 2012 Aug 7;53(9):5292-300. doi: 10.1167/iovs.11-
9165.
15. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-
induced apoptotic cell death. Josefsberg Ben-Yehoshua L, Beider K, Shimoni A, Ostrovsky O,
Samookh M, Peled A, Nagler A. PLoS One. 2012;7(4):e33856. doi:
10.1371/journal.pone.0033856. Epub 2012 Apr 25.
16. Development of novel CXCR4-based therapeutics. Peled A, Wald O, Burger J. Expert Opin
Investig Drugs. 2012 Mar;21(3):341-53. doi: 10.1517/13543784.2012.656197. Epub 2012 Jan
28. Review.
17. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of
hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Peled T,
Shoham H, Aschengrau D, Yackoubov D, Frei G, Rosenheimer G N, Lerrer B, Cohen HY,
Nagler A, Fibach E, Peled A. Exp Hematol. 2012 Apr;40(4):342-55.e1. doi:
10.1016/j.exphem.2011.12.005. Epub 2011 Dec 20.
18. Recruited macrophages control dissemination of group A Streptococcus from infected soft
tissues. Mishalian I, Ordan M, Peled A, Maly A, Eichenbaum MB, Ravins M, Aychek T, Jung
S, Hanski E. J Immunol. 2011 Dec 1;187(11):6022-31. doi: 10.4049/jimmunol.1101385. Epub
2011 Oct 24.
19. Improvement of CXCR4 tracer specificity for PET imaging. Jacobson O, Weiss ID, Szajek LP,
Niu G, Ma Y, Kiesewetter DO, Peled A, Eden HS, Farber JM, Chen X. J Control Release.
2012 Jan 30;157(2):216-23. doi: 10.1016/j.jconrel.2011.09.076. Epub 2011 Sep 22.

4. 20. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. Kirshberg S, Izhar U,
Amir G, Demma J, Vernea F, Beider K, Shlomai Z, Wald H, Zamir G, Shapira OM, Peled A,
Wald O. PLoS One. 2011;6(9):e24856. doi: 10.1371/journal.pone.0024856. Epub 2011 Sep 15.
21. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Burger JA, Stewart
DJ, Wald O, Peled A. Expert Rev Anticancer Ther. 2011 Apr;11(4):621-30. doi:
10.1586/era.11.11. Review.
22. Interaction between neoplastic cells and cancer-associated fibroblasts through the
CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. Wald O, Izhar U,
Amir G, Kirshberg S, Shlomai Z, Zamir G, Peled A, Shapira OM. J Thorac Cardiovasc Surg.
2011 Jun;141(6):1503-12. doi: 10.1016/j.jtcvs.2010.11.056. Epub 2011 Apr
23. Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under
physiological conditions. Weiss ID, Shoham H, Wald O, Wald H, Beider K, Abraham M,
Barashi N, Galun E, Nagler A, Peled A. Cytokine. 2011 Jun;54(3):249-57. doi:
10.1016/j.cyto.2011.01.011. Epub 2011 Mar 3.
24. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor
growth. Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, Pikarsky E, Zeira E,
Eizenberg O, Galun E, Hardan I, Engelhard D, Nagler A, Peled A. Exp Hematol. 2011
Mar;39(3):282-92. doi: 10.1016/j.exphem.2010.11.010. Epub 2010 Dec 5.